Skip to main content
. 2012 Nov 21;7(11):e49699. doi: 10.1371/journal.pone.0049699

Figure 2. Burden of noncervical HPV 6, 11, 16, and 18-related diseases.

Figure 2

The dominant prevalence of HPV 6 and 11 in anogenital warts and RRP, which were associated cumulatively with 56.9% of the total costs of noncervical HPV 6, 11, 16, and 18-related diseases, meant that the fraction of total costs for noncervical diseases attributable to HPV 6 and 11 was at least as large as the fraction of direct costs attributable to HPV 16 and 18.